Source: nytimes

Paradigm: Start-Up Raises $200 Million to Speed Up Drug Trials

New York-based Paradigm has raised a significant amount to simplify clinical trials. Its goal is ambitious, but its challenges are many, researchers say.

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Kent Thoelke's photo - CEO of Paradigm

CEO

Kent Thoelke

CEO Approval Rating

90/100

Read more